---
title: 'Manufacturing Daily Summary: What Happened on October 27, 2026'
headline: Regeneron extends Inmazeb supply contract through 2031 for nearly $270 million
description: Thermo Fisher plans KinetiSol equipment installations in Oregon and Ohio.
url: https://thebench.bio/news/manufacturing/2026-10-27
topic: manufacturing
date: '2026-10-27'
covers:
- '2026-10-27'
date_published: '2026-10-28T00:04:20Z'
date_modified: '2026-10-28T00:04:20Z'
tags:
- Industry
- Software
sources: 2
publisher: TheBench.Bio
---

# Manufacturing Daily Summary: What Happened on October 27, 2026

**Regeneron extends Inmazeb supply contract through 2031 for nearly $270 million**

Thermo Fisher plans KinetiSol equipment installations in Oregon and Ohio.

## Today in brief

Regeneron extended its contract to supply the U.S. government with Inmazeb through 2031, in an agreement worth nearly $270 million. [1] Thermo Fisher plans to install KinetiSol equipment in Bend, Oregon, and Cincinnati, Ohio, making it the only third-party contract development and manufacturing organization offering the Formulator. [2]

## Also worth knowing

- The extended Inmazeb contract builds on Regeneron’s collaboration with the Biomedical Advanced Research and Development Authority, which began in 2020. The additional doses will support national emergency stockpiles. [1]
- Thermo Fisher added KinetiSol, a solvent-free technology for making poorly soluble drugs easier to absorb, to its offerings in 2026. It has installed a lab-scale system in Bend and plans to install a late-stage unit in Cincinnati by the second quarter of 2027. [2]

## The day in numbers

- **Nearly $270 million**: Value of Regeneron’s extended Inmazeb supply contract with the U.S. government. [1]
- **2031**: Year through which the Inmazeb supply extension runs. [1]
- **Second quarter of 2027**: Latest planned timing for Thermo Fisher’s Cincinnati KinetiSol installation. [2]

## Also published

- [Platform Formulations Shift Risk Downstream, Pfizer’s Dr Stephanie Johnson Says](<https://www.biopharminternational.com/view/platform-formulations-shift-risk-downstream-pfizer-stephanie-johnson-says>), BioPharm International
- [Why Lane Security Comes Before Sustainability in Packaging Selection](<https://www.pharmaceuticalcommerce.com/view/why-lane-security-comes-before-sustainability-in-packaging-selection>), Pharmaceutical Commerce
- [Modernize Patient Support Services: Your 3-Step Guide](<https://www.pharmexec.com/view/modernize-patient-support-services-your-3-step-guide>), Pharmaceutical Executive
- [Why BMS Is Screening CMO Partners for Digital Capabilities](<https://www.pharmaceuticalcommerce.com/view/why-bms-is-screening-cmo-partners-for-digital-capabilities>), Pharmaceutical Commerce
- [Reliability in life sciences logistics: What good looks like](<https://pharmaphorum.com/rd/reliability-life-sciences-logistics-what-good-looks>), pharmaphorum
- [The stranded asset problem in microbial custom manufacturing](<https://www.labiotech.eu/partner/lonzathe-stranded-asset-problem-in-microbial-custom-manufacturing/>), Labiotech

## Sources

1. [Regeneron agrees to $270m extension to supply Ebola medicine in US](<https://www.pharmaceutical-technology.com/news/regeneron-270m-extension-ebola-medicine-us/>), Pharmaceutical Technology, 2026-10-27
2. [Thermo Fisher Pairs In Silico Modeling With an Expanded ASD Toolbox at AAPS PharmSci 360](<https://www.biopharminternational.com/view/thermo-fisher-pairs-in-silico-modeling-with-an-expanded-asd-toolbox-at-aaps-pharmsci-360>), BioPharm International, 2026-10-27

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.pharmaceutical-technology.com/news/regeneron-270m-extension-ebola-medicine-us/>
[2]: <https://www.biopharminternational.com/view/thermo-fisher-pairs-in-silico-modeling-with-an-expanded-asd-toolbox-at-aaps-pharmsci-360>